Excelsior Medical Co., Ltd.
TWSE:4104.TW
88.1 (TWD) • At close October 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8,239.256 | 7,186.828 | 6,573.152 | 6,675.494 | 6,457.362 | 6,345.031 | 6,095.337 | 6,205.758 | 6,202.884 | 5,806.677 | 5,740.961 | 5,998.988 | 5,994.336 | 15,355.606 | 14,300.782 |
| Cost of Revenue
| 6,617.165 | 5,672.791 | 5,199.126 | 5,368.92 | 5,218.965 | 5,145.925 | 4,888.446 | 5,008.037 | 4,971.863 | 4,625.724 | 4,586.187 | 4,640.094 | 4,569.757 | 13,828.407 | 13,031.716 |
| Gross Profit
| 1,622.091 | 1,514.037 | 1,374.026 | 1,306.574 | 1,238.397 | 1,199.106 | 1,206.891 | 1,197.721 | 1,231.021 | 1,180.953 | 1,154.774 | 1,358.894 | 1,424.579 | 1,527.199 | 1,269.066 |
| Gross Profit Ratio
| 0.197 | 0.211 | 0.209 | 0.196 | 0.192 | 0.189 | 0.198 | 0.193 | 0.198 | 0.203 | 0.201 | 0.227 | 0.238 | 0.099 | 0.089 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 350.904 | 308.085 | 261.402 | 278.617 | 304.073 | 259.316 | 270 | 345.132 | 383.061 | 356.33 | 349.455 | 395.914 | 352.965 | 385.83 | 346.515 |
| Selling & Marketing Expenses
| 622.683 | 585.199 | 509.139 | 495.902 | 463.877 | 489.605 | 483.736 | 472.092 | 500.645 | 479.339 | 497.542 | 576.658 | 580.253 | 666.367 | 580.976 |
| SG&A
| 919.211 | 893.284 | 770.541 | 774.519 | 767.95 | 748.921 | 753.736 | 817.224 | 883.706 | 835.669 | 846.997 | 972.572 | 933.218 | 1,052.197 | 927.491 |
| Other Expenses
| -38.636 | -66.039 | -78.376 | 0.076 | 2.342 | 72.811 | 25.883 | 117.384 | 163.512 | 120.287 | 171.516 | 9.205 | 18.334 | 33.73 | 11.376 |
| Operating Expenses
| 919.211 | 893.284 | 770.541 | 774.595 | 770.292 | 748.862 | 754.329 | 818.225 | 882.848 | 837.455 | 846.121 | 972.572 | 933.218 | 1,052.197 | 927.491 |
| Operating Income
| 702.88 | 869.857 | 769.234 | 843.06 | 774.711 | 450.244 | 452.562 | 379.496 | 348.173 | 343.498 | 308.653 | 386.322 | 491.361 | 475.002 | 341.575 |
| Operating Income Ratio
| 0.085 | 0.121 | 0.117 | 0.126 | 0.12 | 0.071 | 0.074 | 0.061 | 0.056 | 0.059 | 0.054 | 0.064 | 0.082 | 0.031 | 0.024 |
| Total Other Income Expenses Net
| 98.898 | 93.843 | 104.502 | -13.677 | -27.886 | 198.256 | 101.675 | 199.118 | 198.844 | 126.916 | 106.048 | 70.334 | 53.935 | 61.456 | 116.914 |
| Income Before Tax
| 801.778 | 963.7 | 873.736 | 829.383 | 746.825 | 648.5 | 554.237 | 578.614 | 547.017 | 470.414 | 414.701 | 456.656 | 545.296 | 536.458 | 458.489 |
| Income Before Tax Ratio
| 0.097 | 0.134 | 0.133 | 0.124 | 0.116 | 0.102 | 0.091 | 0.093 | 0.088 | 0.081 | 0.072 | 0.076 | 0.091 | 0.035 | 0.032 |
| Income Tax Expense
| 221.23 | 178.399 | 151.447 | 160.297 | 124.551 | 100.077 | 83.229 | 101.312 | 79.271 | 102.369 | 88.296 | 95.656 | 97.326 | 101.724 | 131.856 |
| Net Income
| 746.605 | 667.453 | 607.149 | 571.67 | 514.755 | 451.562 | 399.047 | 389.557 | 379 | 285.681 | 299.942 | 275.785 | 333.97 | 355.692 | 311.95 |
| Net Income Ratio
| 0.091 | 0.093 | 0.092 | 0.086 | 0.08 | 0.071 | 0.065 | 0.063 | 0.061 | 0.049 | 0.052 | 0.046 | 0.056 | 0.023 | 0.022 |
| EPS
| 4.8 | 4.29 | 3.9 | 3.69 | 3.64 | 3.34 | 2.94 | 2.91 | 3.08 | 2.38 | 2.5 | 2.25 | 2.77 | 3.17 | 3.07 |
| EPS Diluted
| 4.78 | 4.27 | 3.88 | 3.67 | 3.62 | 3.34 | 2.92 | 2.86 | 3.01 | 2.37 | 2.45 | 2.22 | 2.72 | 3.15 | 3 |
| EBITDA
| 968.556 | 1,092.295 | 972.188 | 1,010.527 | 934.952 | 762.937 | 670.833 | 714.498 | 707.822 | 625.306 | 579.361 | 560.357 | 691.874 | 699.952 | 548.001 |
| EBITDA Ratio
| 0.118 | 0.152 | 0.148 | 0.151 | 0.145 | 0.12 | 0.11 | 0.115 | 0.114 | 0.108 | 0.101 | 0.093 | 0.115 | 0.046 | 0.038 |